The EvidenceCare Pneumonia pathway allows the provider to determine the optimal treatment protocol for a patient with suspected Pneumonia. The protocol is broken down into management of patients with Community-Acquired (CAP), Hospital-Acquired (HAP), and Ventilator-Associated Pneumonia (VAP). In Community-Acquired Pneumonia patients the user is guided through risk stratification of the patient’s clinical severity using the CURB-65, the Pneumonia Severity Index (PSI), or clinical gestalt. Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) consideration of whether the patient has any MRSA or Pseudomonas risk factors are taken into account to determine the optimal antibiotic regimen. Guidelines that are used in this pathway include the new 2016 IDSA HAP/VAP Guidelines, the NICE Guidelines for Pneumonia, and the IDSA/ATS Community-Acquired Pneumonia Guidelines.